Kamada Ltd. (KMDA +0.5%) inks an agreement with Alvotech to commercialize the latter’s portfolio of six biosimilars in Israel, once approved. The first product, PF708 (branded as Bonsity), a biosimilar to Eli Lilly’s osteoporosis med Forteo (teriparatide), should be launched in 2022.
Financial terms are not disclosed.
On cue from its ASLAN004-stoked run-up, ASLAN Pharmaceuticals (ASLN +49.2%) commences a public offering of American Depositary Shares (ADSs). Price, volume and terms have yet to be announced.
The U.S. Federal Trade Commission (FTC) grants antitrust clearance for Amgen’s (AMGN -0.5%) previously announced collaboration with BeiGene (BGNE -0.6%) that includes a $2.7B investment (20.5% stake) in the Chinese biotech.
Aleafia Health (OTCQX:ALEAF) is up 4% in early trade in response to an order from a licensed producer in Canada for 2,840 kg of dried cannabis flower at $2.50 per gram for a total of $7.1M. The transaction, consisting of three shipments, will be completed before the end of next month.
Mylan owns exclusive commercialization rights in the U.S., Canada, Japan, Australia, New Zealand, the EU and European Free Trade Association countries. Biocon has co-exclusive rights with Mylan in the rest of the world.